Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 13, 2015
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 03, 2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Journal: Haematologica
Published: March 05, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Journal: The Lancet. Oncology
Published: January 04, 2015
Showing 1-5 of 5
Last Updated: 09/26/2026